Curated News
By: NewsRamp Editorial Staff
September 08, 2026
VERAXA Biotech Appoints Raju Willener as CFO to Drive Capital Strategy
TLDR
- VERAXA's new CFO Raju Willener's 30 years of financial leadership and global markets experience strengthens capital strategy and supports pipeline growth.
- VERAXA Biotech appoints Raju Willener as CFO, who will manage capital strategy and support the BiTAC platform, reporting to CEO Christoph Antz.
- VERAXA aims to improve cancer therapy through innovative antibody-based treatments, now with a seasoned CFO to help bring these advances to patients.
- VERAXA's new CFO previously managed investments exceeding CHF 30 billion, bringing a wealth of experience to the biotech's fight against cancer.
Impact - Why it Matters
This appointment is crucial for VERAXA Biotech as it signals a strengthened financial leadership team to navigate the complex landscape of biotech financing and strategic growth. With Willener's extensive experience in capital markets and asset management, the company is better positioned to secure funding for its promising BiTAC(R) technology and oncology pipeline, potentially accelerating the development of next-generation cancer therapies. For investors and patients, this move could translate into more robust clinical advancement and a clearer path to bringing innovative treatments to market, impacting the future of cancer care.
Summary
LOS ANGELES, CA - September 8, 2026 (NEWMEDIAWIRE) - VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has announced the appointment of Raju Willener as its new chief financial officer, effective immediately. Willener brings over three decades of international financial leadership experience, spanning global capital markets, investment banking, corporate finance, asset management, and strategic leadership. He will report directly to CEO and Co-Founder Christoph Antz, Ph.D., and is expected to support the company's capital strategy, strategic opportunities, and the continued development of its proprietary BiTAC(R) technology platform and oncology pipeline. Prior to joining VERAXA, Willener served as director of corporate development at Exentis Group AG before being appointed CFO in 2025, where he led M&A initiatives, financial strategy, and key corporate functions. Earlier in his career, he held senior executive and investment positions overseeing corporate finance, capital markets, investor relations, and investment portfolios exceeding CHF 30 billion in assets under management.
VERAXA Biotech is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research. The appointment of Willener is a strategic move to strengthen the company's financial leadership as it progresses its innovative cancer therapies. The full press release is available at https://nnw.fm/jcHOU, and the latest news and updates relating to VRXA can be found in the company's newsroom at https://ibn.fm/VRXA.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, VERAXA Biotech Appoints Raju Willener as CFO to Drive Capital Strategy
